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Abstract
Background: After local excision of early rectal cancer, revision radical resection is recommended for patients with
high-risk pathologic stage T1 (pT1) or pT2 cancer, but the revision procedure has high morbidity rates. We evaluated the
efficacy of adjuvant concurrent chemoradiotherapy (CCRT) for reducing recurrence after local excision in these patients.
Methods: Eighty-three patients with high-risk pT1 or pT2 rectal cancer underwent postoperative adjuvant CCRT after
local excision. We defined high-risk features as pT1 having tumor size ≤3 cm, and/or resection margin (RM) ≤3 mm,
and/or lymphovascular invasion (LVI), and/or non-full thickness excision such as endoscopic mucosal resection (EMR) or
endoscopic submucosal dissection (ESD), or unknown records regarding those features, or pT2 cancer. Radiotherapy was
administered with a median dose of 50.4 Gy in 1.8 Gy fraction size over 5–7 weeks. Concurrent 5-fluorouracil and
leucovorin were administered for 4 days in the first and fifth weeks of radiotherapy.
Results: The median interval between local excision and radiotherapy was 34 (range, 11–104) days. Fifteen patients
(18.1 %) had stage pT2 tumors, 22 (26.5 %) had RM of ≥3 mm, and 21 (25.3 %) had tumors of ≥3 cm in size. Thirteen
patients (15.7 %) had LVI. Transanal excision was performed in 58 patients (69.9 %) and 25 patients (30.1 %) underwent
EMR or ESD. The median follow-up was 61 months. The 5-year overall survival (OS), locoregional relapse-free survival
(LRFS), and disease-free survival (DFS) rates for all patients were 94.9, 91.0, and 89.8 %, respectively. Multivariate analysis
did not identify any significant factors for OS or LRFS, but the only significant factor affecting DFS was the pT
stage (p = 0.027).
Conclusions: In patients with high-risk pT1 rectal cancer, adjuvant CCRT after local excision could be an effective
alternative treatment instead of revision radical resection. However, patients with pT2 stage showed inferior DFS
compared to pT1.
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Background
Radical surgery has been the standard of treatment for
patients with rectal cancer and adjuvant concurrent che-
moradiotherapy (CCRT) is often recommended in order
to decrease the risk of recurrence for patients with locally
advanced rectal cancer. A randomized controlled study
comparing adjuvant CCRT with neoadjuvant CCRT has
showed more sphincter preservation, a decreased rate of
pelvic recurrence, and a lower incidence of treatment-
related toxicities in the neoadjuvant CCRT group [1]. In
selected cases, local excision after neoadjuvant CCRT
had comparable oncologic outcomes to radical surgery,
with fewer complications [2], and local recurrence rates
of <20 % have been reported in patients with stage T2 tu-
mors after local excision with neoadjuvant CCRT [3, 4].
Transanal excision (TAE) can be performed as an ini-
tial treatment in patients with early rectal cancers who
have well to moderately differentiated stage T1 tumors
that are <30 % of the circumference, <3 cm in size, mo-
bile, non-fixed, and without lymphovascular invasion
(LVI) or perineural invasion [5, 6]. Local excision should
be performed in patients with no evidence of lymph-
adenopathy on pretreatment imaging because lymph
node metastasis has been reported at rate of 17 to 31 %
in patients with pathologic stage T1 (pT1) and pT2 rectal
cancers [7].
TAE alone has been associated with a higher instance
of local recurrence (2.7 vs. 13.2 %, p = 0.001) and inferior
disease-specific survival when compared to radical sur-
gery for tumors with high-risk pathologic features [5],
and revision radical resection is often necessary after local
excision for patients with these tumors [8, 9]. Radical sur-
gery has a 2–3 % perioperative mortality rate and 20–30 %
complication rate, including bowel, bladder, and sexual
dysfunction and permanent colostomy [10]. Local excision
and adjuvant CCRT have been attempted instead of revi-
sion radical surgery in order to avoid major morbidities,
and local excision with adjuvant CCRT may offer better
oncologic outcomes than local excision alone [11–14].
However, the efficacy of adjuvant CCRT after local exci-
sion remains controversial, and evidence is lacking, as
there are few published reports so far.
We present a retrospective single-center analysis of
survival outcomes in a relatively large cohort to investi-
gate the role of adjuvant CCRT after local excision as an
alternative to revision radical surgery in patients with
early stage high-risk rectal cancers.
Methods
Patient eligibility
Patients who received adjuvant CCRT after local excision
of rectal cancer between January 2004 and December 2012
were eligible for inclusion. Clinical imaging before local
excision included abdominal-pelvic computed tomography
(CT) and/or pelvic magnetic resonance imaging (MRI),
and chest CT. Tumor stage was classified in accordance
with the American Joint Committee on Cancer staging
system, seventh edition. Eligibility criteria included a histo-
logical diagnosis of adenocarcinoma, pT1, after local exci-
sion of the primary rectal cancer, with high-risk features
including tumor size ≥3 cm, and/or resection margin
(RM) ≤3 mm, and/or LVI, and/or non-fullthickness ex-
cision such as endoscopic mucosal resection (EMR) or
endoscopic submucosal dissection (ESD), or unknown
records regarding those features, or pT2 cancer. Patients
with no evidence of distant metastasis, no previous history
of other cancers, and no previous pelvic radiotherapy were
eligible in this analysis. Institutional review board at our
institute approved this study.
Adjuvant treatments
Radiotherapy was performed with 6-MV or 10-MV X-rays
via three- or four-field box technique for two-dimensional
(2D) or three-dimensional (3D) conformal radiotherapy.
The superior border of the 2D field was the sacral prom-
ontory, the inferior border was 3 cm distal to the tumor
or the inferior obturator foramen, the lateral border was
1 cm from the bony pelvis, and the anterior and posterior
borders of the lateral portals were at the posterior sym-
physis pubis and at 1 cm behind the anterior bony sacrum.
The clinical target volume (CTV) for 3D conformal radio-
therapy included the primary tumor bed, the mesorectum,
and the presacral, obturator, internal iliac, and distal com-
mon iliac lymph nodes. The PTV was defined as 0.5 cm
margin around the CTV in all directions. The planned
dose to PTV was up to 45.0 Gy in 1.8 Gy fraction size over
5 weeks and an additional boost dose of 5.4 Gy was ad-
ministered to tumor bed. A concurrent chemotherapy
regimen of 5-fluorouracil (5-FU; 425 mg/m2/day) and
leucovorin (LV; 20 mg/m2/day) was administered for
4 days during weeks 1 and 5 of radiotherapy, and after
completion of the CCRT, adjuvant chemotherapy con-
sisting of 5-FU (425 mg/m2/day) and LV (20 mg/m2/day)
administered for 5 days every 4 weeks, for up to four
cycles, was recommended.
Follow-up and statistical analysis
Regular follow-up visits were scheduled at 3-month in-
tervals following completion of radiotherapy, including
sigmoidoscopy and abdominal-pelvic CT or pelvic MRI
for up to 2 years, and at 4- to 6-month intervals for the
next 3 years. Chest CT was also scheduled to be checked
at 6-month intervals. Treatment failure was defined as
showing newly developed soft tissue mass or lymph
node on CT or MRI, and pathologic confirmation was
required for diagnosis of local recurrence. Overall sur-
vival (OS) was defined as the time from the start of
CCRT to death from any cause or the last follow-up.
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Locoregional relapse-free survival (LRFS) was defined as
survival without locoregional recurrence from the start
date of CCRT to the date of last follow-up or death from
any cause. Disease-free survival (DFS) was defined as the
time from the start of therapy to the date of treatment
failure or last follow-up. Survival rates were calculated
up to 60 months of follow-up in order to remove bias
due to death from natural causes among elderly patients
surviving more than 60 months.
The Kaplan-Meier method was used to plot survival
curves, which were analyzed using log-rank tests to de-
termine prognostic factors in univariate analysis. A Cox
regression model was used to identify prognostic factors
in the multivariate analysis. All statistical analyses were
performed using SPSS, version 19.0 (SPSS Inc., Chicago,
IL, USA). A statistically significant difference between
groups was indicated at p < 0.05. Adverse events were
defined according to the National Cancer Institute




During the study period, a total of 90 patients received
adjuvant CCRT after local excision for early rectal cancer.
Of these, seven patients were excluded, including three
who had carcinoma in situ, two who did not have any
high-risk features, one who chose to discontinue RT after
7.2 Gy in four fractions, and one who had colectomy for
transverse colon cancer 1 month before TAE for the rectal
tumor (Fig. 1). Thus, 83 patients (57 men and 26 women,
median age 66 years) were included in the study (Table 1).
The median interval between local excision and the
start of CCRT was 34 days (range 11–104). Fifteen pa-
tients (18.1 %) had stage pT2 tumors, 22 (26.5 %) had
RM of ≤3 mm, and 21 (25.3 %) had tumors of ≥3 cm in
size. Thirteen patients (15.7 %) had LVI. TAE was per-
formed in 58 patients (69.9 %) and 25 patients (30.1 %)
underwent EMR or ESD. The median radiotherapy dose
was 50.4 Gy (range 39.6–59.4 Gy). There were two pa-
tients in the study group (2.4 %) who chose not to
Fig. 1 Eligible patients who received adjuvant chemoradiotherapy after local excision for early rectal cancer with high-risk features
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receive chemotherapy, and therefore had RT only; there
were 14 patients (16.9 %) who consented to an additional
course of adjuvant chemotherapy following the CCRT: 1
of these received five cycles of oral therapy with tegafur
and uracil (300/672 mg/m2/day) for 4 weeks per cycle due
to travel difficulties; all of the others were to receive the
regimen described above (Table 1).
Survival and prognostic factors
At the time of the final analysis, 75 patients (90.4 %) had
survived without disease and two (2.4 %) were alive with
disease. The median duration of follow-up was 61 months.
Five-year OS for all 83 patients was 94.9 %, with LRFS of
91 %, and DFS of 89.8 % (Fig. 2). The variables of sex, age,
tumor location, serum carcinoembryonic antigen levels,
Table 1 Patient, tumor, and treatment characteristics





















Well differentiated 46 55.4
Moderately differentiated 32 38.6











> 3 mm 3 3.6
≤ 3 mm 22 26.5
Unknown 58 69.9
Local excision
Endoscopic mucosal resection 21 25.3
Endoscopic submucosal dissection 4 4.8




Table 1 Patient, tumor, and treatment characteristics
(Continued)
Concurrent chemotherapy




No chemotherapy 69 83.1
5-FU 13 15.7
oral 5-FU prodrug 1 1.2
FL 5-fluorouracil + leucovorin, FP 5-fluorouracil + cisplatin, 5-FU 5-fluorouracil
Fig. 2 Overall survival (OS), locoregional relapse-free survival (LRFS),
and disease-free survival (DFS) in entire patient cohort
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tumor size, pathologic T stage, RM, LVI, type of local exci-
sion, radiation dose, and adjuvant chemotherapy were
used for both univariate and multivariate analysis. Age
was the only significant factor associated with OS on
univariate analysis (p = 0.031), and this may have been
because death from any cause was considered as an
event when calculating survival. According to DFS,
pathologic T stage showed statistical significance in uni-
variate analysis (p = 0.015). On multivariate analysis, there
were no significant factors for OS or LRFS (Table 2), but
pathologic T stage was the only significant factor influen-
cing DFS (p = 0.027).
Table 2 Prognostic factors related with overall survival (OS), locoregional relapse-free survival (LRFS), and disease-free survival (DFS)
OS LRFS DFS
Univariate Multivariate Univariate Multivariate Univariate Multivariate
(No. of patients) 5-year rate (%) p-value 5-year rate (%) p-value 5-year rate (%) p-value
Sex n-s n-s n-s
Male (57) 94.4 92.6 90.9
Female (26) 95.8 87.6 87.6
Age n-s n-s n-s
< 70 (58) 98.2a 94.8 93.1
≥ 70 (25) 86.4 81.0 81.0
Location from anal verge n-s n-s n-s
< 5 cm (33) 96.7 93.6 90.7
≥ 5 cm (50) 93.7 89.4 89.4
CEA level n-s n-s n-s
< 3 ng/ml (49) 100 95.6 93.6
≥ 3 ng/ml (34)b 87.0 84.0 84.3
Tumor size n-s n-s n-s
< 3 cm (62) 94.9 89.7 88.1
≥ 3 cm (21) 94.7 94.7 94.7
T-stage n-s n-s 0.027 (HR: 4.8, 95 % CI: 1.2–19.1)
1 (68) 95.2 93.7 93.8a
2 (15) 93.3 80.0 73.3
Resection margin n-s n-s n-s
> 3 mm (3) 100 100 100
≤ 3 mm (22) 95.5 86.4 81.8
Unknown (58) 94.3 92.1 92.1
LVI n-s n-s n-s
No (41) 92.1 87.1 84.9
Yes (13) 92.3 83.9 83.9
Unknown (29) 100 100 100
Local excision n-s n-s n-s
EMR or ESD (26) 92.0 88.1 88.1
TAE (57) 96.2 92.2 90.5
Radiation dose n-s n-s n-s
> 50.4 Gy (8) 100 100 100
≤ 50.4 Gy (75) 94.3 90.0 88.7
Adjuvant chemotherapy n-s n-s n-s
Yes (14) 100 92.9 92.9
No (69) 93.9 90.7 89.3
N-S not significant, LVI lymphovascular invasion, EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, TAE transanal excision, HR hazard
ratio, CI confidence interval, astatistically significant in univariate analysis, b Nine patients of unknown CEA level were included in this subgroup
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Treatment failures and toxicities
Two of five patients (2.4 %) with observed treatment
failure had isolated local recurrences, two (2.4 %) had
isolated distant recurrences, and one (1.2 %) had simul-
taneous local and distant recurrence. No regional treat-
ment failures were observed in any patient. Among the
five patients with local and distant recurrences, four
(80 %) had stage pT2 tumors or surgical RM of ≤3 mm.
Five-year LRFS for patients with stage pT1 vs. pT2 tu-
mors was 93.7 vs. 80.0 %, respectively, but this difference
was not significant (p = 0.091). However, the 5-year DFS
did differ significantly, at 93.8 % for patients with stage
T1 tumors and 73.3 % for those with stage T2 tumors
(p = 0.015) (Fig. 3). Regarding the two patients who had
isolated local failure, one patient received intensity-
modulated re-irradiation with 5-FU after re-excision and
the other underwent salvage laparoscopic abdominoperi-
neal resection with adjuvant chemotherapy and they had
survived without disease at the last follow-up. The pa-
tient with loco-distant recurrence had progressive dis-
ease despite salvage chemotherapy, and one of the two
patients who had isolated distant recurrences was alive
after salvage liver metastasectomy, while the other died
of disease (Table 3). Grade 2 proctitis occurred in nine
patients (10.8 %), and no grade 3 or higher acute toxic-
ities developed. There were no patients who had Grade
2 or higher late toxicities. Nine patients (10.8 %) showed
proctitis finding without any symptom on regular
follow-up proctoscopy. There were no patients who had
symptom relating anal sphincter dysfunction.
Discussion
In this study, adjuvant CCRT after local excision was
shown to have acceptable oncologic outcomes without
severe complications in patients with early rectal cancers
that exhibited known high-risk features for locoregional
recurrence. Five-year LRFS was 91 % and DFS was
89.8 %. There were no significant factors related to OS
on multivariate analysis. Neither univariate nor multi-
variate analysis identified significant factors associated
with LRFS in the study, but the only significant factor af-
fecting DFS was the pathologic T stage. This result im-
plies that adjuvant CCRT could allow excellent tumor
control for patients with high-risk stage T1 tumors.
However, the patients with pT2 tumors survived signifi-
cantly shorter DFS in this study. In the non-randomized
prospective trial, 51 patients with T2 cancers received
CRT after local excision, and 7/51 (14 %) experienced
isolated local recurrence with 4 years median follow-up
[15]. But more patients (18 %) had local recurrence in
the updated results with more than 7 years median
follow-up [16].
Local excision of early-stage rectal cancers is becoming
a more common treatment approach [12]. However,
patients may be at higher risk of recurrence after local
excision compared to conventional radical resection
procedures. Nash et al. reported higher recurrence
rates in patients who had local excision compared with
those who underwent radical resection for T1 rectal
cancer (13.2 vs. 2.7 %, p = 0.001) [5], and local excision
alone for stage pT2 tumors has been associated with a
recurrence rate of up to 37 %, requiring salvage by
radical resection where possible [17]. Adjuvant CCRT
after local excision of stage T1 and T2 tumors has been
associated with reduced local recurrence rates in sev-
eral previous studies [11–14]. In one of these, the local
recurrence rate among patients with stage T2 tumors
who received adjuvant radiotherapy was 9 vs. 36 %
among those who did not have adjuvant treatments
[13]. In another, among 27 T1 patients, four of 17 pa-
tients with stage T1 tumors who had local excision
without adjuvant therapy developed local recurrence
(24 %) while remaining 10 patients with adjuvant
CCRT did not [14].
The benefits of local excision may include reduced
overall morbidity, avoidance of permanent colostomy
instances, reduced mortality, and shorter hospital stay
[18]. Morbidity rates of 5.6 vs. 14.5 % (p < 0.001) have
been reported for patients undergoing local excision vs.
radical resection for the initial treatment of stage T1
tumors [19]. However, salvage surgery for recurrence
after initial local excision might result in poor oncologic
outcomes and high morbidity [20]. In our study, only
three of 83 patients (3.6 %) had local recurrence and
none had severe surgical morbidities, such as are seen
Fig. 3 Disease-free survival according to pathologic T-stage
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more frequently after radical resection. However, local
excision alone cannot provide information on the re-
gional lymph node status, and there is a known 5–10 %
risk of occult lymph node metastases in patients with
stage T1 tumors and a 20–35 % risk in those with stage
T2 lesions [7]. The finding that there were no regional
recurrences among the patients in our study suggests
that adjuvant CCRT after local excision may have de-
creased the risk of regional recurrence by controlling re-
gional subclinical disease.
There are several well-known risk factors for recur-
rence after local excision [21]. Stage T2 lesions have a
higher rate of local recurrence compared with T1 lesions
[19], and radical surgery or adjuvant treatment should
be routine for patients with stage pT2 tumors after local
excision. Patients with stage pT2 tumors who were
treated with local excision followed by RT have been
shown to have improved OS compared to those who
have local excision only [12]. Rackley et al. recommend
radical resection instead of local excision with adjuvant
therapy for patients with stageT2 tumors because of
inferior local control compared to T1 disease [22].
However, they do recommend local excision with adju-
vant radiotherapy as a good alternative for patients
with stage pT2 tumors who are not candidates for
revision radical surgery. Failure to obtain a clear RM is
also a well-known risk factor for local recurrence.
Gopaul et al. reported that the RM was a significant
factor in local treatment failure in patients treated with
local excision [13]. The National Comprehensive Cancer
Network® guideline recommends RM of >3 mm for TAE
[23]. In our study, LRFS and DFS were worse among 22
patients with RM of ≤3 mm compared to those with RM
of >3 mm, but the difference was not significant (Table 2).
Radiation doses may be varied according to the extent
of the RM. In one series, a dose of 50–56 Gy was recom-
mended in general, but if the RM was <3 mm, the dose
was raised to 59.4–65 Gy. One in 33 patients with margins
of <3 mm and one in 18 patients with margins of ≥3 mm
had locoregional recurrence [11]. In our study, all three
patients with local recurrence had radiation doses of
50.4 Gy, but they had stage pT2 tumors or RM of ≤3 mm
(Table 3). There were no treatment failures among eight
patients who received doses of >50.4 Gy. Among these
eight patients, four (50 %) had stage pT2 tumors or RM
of ≤3 mm, and all received doses of 54.0 Gy,2 having
LVI received 52.2 Gy and 54.0 Gy, respectively, and no
details on RM were available for the remaining two,
who received 59.4 Gy and 54.0 Gy, respectively.
There are some limitations to this study. First, this
study is limited by the retrospective nature and the study
period spanned 9 years. During that period, there might
be some inherent biases among patient or treatment
characteristics. We could not obtain pathological infor-
mation regarding high-risk pathologic features such as
LVI or RM for many patients, as shown in Table 1. How-
ever, we classified these patients as having potentially
high-risk features, considering that referral by the sur-
geon for adjuvant CCRT might be due to the surgeon's
observation of potential high-risk features. Secondly, 14
patients (16.5 %) received adjuvant chemotherapy after
completion of adjuvant CCRT. However, there were but
no significant differences in clinicopathological features
between patients who received adjuvant chemotherapy
and those who did not (data not shown).
Conclusion
We found adjuvant CCRT after local excision could be
an effective alternative treatment instead of revision radical
resection in patients with high-risk pT1 rectal cancer.






Table 3 Characteristics of patients with treatment failure
Sex Age Initial CEA pT Excision Margin Radiation dose Disease-free
interval (Months)
Failure site Salvage treatment Months after
recurrence
Last status


















Male 67 unknown 1 TAE unknown 48.6 Gy 23 liver No 9 Dead
with disease
CEA carcinoembryonic antigen, pT pathologic T-stage, TAE transanal excision, IFF in-field failure, CCRT concurrent chemoradiotherapy, APR abdominoperineal resection,
5-FU 5-fluorouracil, EMR endoscopic mucosal resection
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